Clinical Trials on Choroidal Melanoma in Switzerland

Total 153 results

University Hospital, Basel, Switzerland
Anaveon AG

Recruiting

ACT-TIL and ANV419 for Advanced Melanoma. (BaseTIL-03M)

Advanced Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois

Completed

Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma

Ocular Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Vista Klinik

Completed

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis
QLT Inc.

Completed

Photodynamic Therapy in Occult-Only Lesions (POOL)

Age-Related Macular Degeneration

Switzerland
Hoffmann-La Roche

Completed

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Malignant Melanoma

Switzerland
University of Zurich

Completed

Ipilimumab-induced Lung Toxicity: Observational Study (Ipi-Lu-Tox)

Metastatic Melanoma

Switzerland
Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Metastatic Melanoma

Switzerland
Novartis

Completed

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Markus Joerger

Recruiting

Tinostamustine and Nivolumab in Advanced Melanoma (ENIgMA)

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Novartis

Completed

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD)

Switzerland
Vista Klinik

Completed

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
University Hospital, Geneva

Suspended

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Stage IB Skin Melanoma | Stages III Skin Melanoma | Stages II Skin Melanoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

Switzerland
Prof. Serge Leyvraz

Completed

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Melanoma (Skin)

Switzerland
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
University of Zurich

Completed

Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine

Melanoma Stage III or IV | No Prior Chemotherapy

Switzerland
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Novartis Pharmaceuticals

Completed

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Choroidal Neovascularization (CNV)

Korea, Republic of, Germany, Russian Federation, Turkey, Australia, Hungary, Switzerland, Italy, Lithuania, Denmark, Peru, Spain, Portugal, Canada, France, Latvia, Greece, Slovakia, Czech Republic, Poland, Singapore
Amgen

No longer available

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Unresected Stage IIIB to IVM1c Melanoma

Switzerland
Novartis

Completed

Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients

Metastatic Melanoma

Switzerland
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Prof. Dr. Silke Gillessen

Terminated

Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma

Melanoma

Switzerland
University of Lausanne Hospitals
Fond'action contre le cancer; Barletta Foundation; NCCR (National Center of Competence...

Suspended

Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients

Melanoma

Switzerland
University Hospital, Basel, Switzerland

Completed

Melanoma Detection in Switzerland With VECTRA (MELVEC)

Melanoma (Skin)

Switzerland
University of Zurich

Completed

Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel

Melanoma

Switzerland
John O. Prior

Terminated

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma (Tilmanocept)

Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Novartis

Terminated

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration | Choroidal Neovascularization

United Kingdom, Spain, Netherlands, Hungary, Italy, Denmark, Belgium, Austria, France, Germany, Poland, Switzerland
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois

Recruiting

Irradiation of Melanoma in a Pulse (IMPulse)

Metastasis From Malignant Melanoma of Skin (Diagnosis)

Switzerland
University Hospital Inselspital, Berne

Completed

Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)

Melanoma

Switzerland
Pfizer

Completed

Use of 852A in Metastatic Cutaneous Melanoma.

Melanoma | Unresectable Metatstatic Cutaneous Melanoma

Switzerland, Germany, France
Philogen S.p.A.
Eudax S.r.l.

Terminated

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Metastatic Melanoma

Switzerland, Italy, Austria, Germany
Centre Hospitalier Universitaire Vaudois

Completed

Immunotherapy of Melanoma Patients

Melanoma

Switzerland
Novartis Pharmaceuticals

Completed

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (CHIR-265-MEL01)

Metastatic Melanoma

Switzerland, United States
Institut Curie
Servier; UNICANCER

Completed

Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma (FOTEADJ)

Uveal Melanoma

France, Switzerland
Hoffmann-La Roche

Completed

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

Malignant Melanoma

Switzerland
University Hospital, Basel, Switzerland

Completed

Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma

Melanoma

Switzerland
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Onxeo

Completed

A Study to Assess APO866 for the Treatment of Advanced Melanoma

Melanoma

Austria, France, Germany, Switzerland
European Organisation for Research and Treatment...

Active, not recruiting

Minimal SN Tumor Burden (Minitub)

Cutaneous Melanoma

France, Italy, Switzerland, Belgium, Netherlands, Germany, Poland, Slovenia, United Kingdom, Spain
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

France, Switzerland, Norway, Belgium, United Kingdom, Germany, Austria, Portugal, Italy
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
University Hospital Inselspital, Berne

Completed

Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study (LIMIT)

Merkel Cell Carcinoma | Malignant Melanoma

Switzerland
European Organisation for Research and Treatment...

Terminated

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Metastatic Cancer | Intraocular Melanoma

Switzerland, Italy, United Kingdom, Poland

Clinical Trials on Choroidal Melanoma in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations